Relugolix Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

Total Trials

Recruiting

Completed

19,403

Total Enrollment

States

Relugolix Evidence & Publications

54 peer-reviewed publications + per-arm primary-outcome data from 11 pivotal trials.

See published evidence →

Relugolix Clinical Trials

Sortable list of all 53 Relugolix trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

Relugolix History and Updates

Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Relugolix — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Relugolix updates

See full history →

Estradiol and Norethindrone Acetate Label Adds Boxed Warning for Major Risks· May 29, 2026
Relugolix Combination Therapy Shows Contraceptive Efficacy in Phase 3 Trial· May 13, 2026
Relugolix Phase 3 Endometriosis Trial Completes Primary Data Collection· Feb 15, 2026
Relugolix Label Updated with Boxed Warning on Cardiovascular Risk· Jan 29, 2026
Relugolix Real-World Study Describes Prostate Cancer Patient Characteristics· Dec 11, 2025
Estradiol Label Receives New Boxed Warning for Serious Risks· Nov 25, 2025
Microgestin 1/20 Label Adds Boxed Warning on Cardiovascular Risks· Nov 12, 2025
Orgovyx Label Updated for Advanced Prostate Cancer Indication· Oct 10, 2025

What Is Relugolix?

Relugolix is an FDA-approved medication for prostate cancer. It functions as a gonadotropin-releasing hormone (GnRH) antagonist. This mechanism involves blocking the release of specific hormones from the pituitary gland, which in turn reduces the production of testosterone. By lowering testosterone levels, Relugolix acts as an androgen deprivation therapy (ADT), which can help slow the growth of hormone-sensitive cancers.

In addition to its approved use, Relugolix is currently being investigated in clinical trials for a variety of other conditions. These include prostate adenocarcinoma, different stages of prostate cancer, uterine fibroids, heavy menstrual bleeding, endometriosis, biochemically recurrent prostate carcinoma, and pregnancy complications. A total of 53 clinical trials have studied Relugolix, enrolling over 19,403 participants. The first trial began in 2014, and research continues with 21 trials currently recruiting new participants.

Uses and Conditions Under Study

Relugolix is extensively studied for various forms of prostate cancer. This includes prostate adenocarcinoma, different stages of prostate cancer (such as Stage III and Stage IIC), and biochemically recurrent prostate carcinoma. Prostate cancer is often hormone-sensitive, meaning its growth can be influenced by testosterone. As an androgen deprivation therapy (ADT), Relugolix works by lowering testosterone levels, which can help manage the disease. A total of 34 trials are investigating Relugolix for these prostate cancer-related conditions, with sponsors including Myovant Sciences GmbH and Sumitomo Pharma Switzerland GmbH.

The medication is also being explored for conditions affecting women's reproductive health. Uterine fibroids, which can lead to heavy menstrual bleeding, are the focus of 12 trials. Relugolix, sometimes used as a combination therapy (e.g., with estradiol and norethindrone acetate), may help by reducing estrogen levels, which can shrink fibroids and lessen bleeding. Similarly, endometriosis, a painful condition where tissue similar to the uterine lining grows outside the uterus, is being studied in 4 trials. By reducing estrogen, Relugolix may help alleviate the symptoms associated with endometriosis, as seen in studies like NCT04860124.

Additionally, Relugolix is being investigated in 2 trials for pregnancy complications.

Dosing

Relugolix is primarily administered as an oral tablet. It is also studied in various combination therapies, often as a single pill containing multiple active ingredients.

Different strengths of Relugolix have been investigated in clinical trials. These include 40 mg, 80 mg, and 120 mg. For prostate cancer, a dose of 120 mg daily for extended periods, such as 12 months, has been studied. This may be given as a standalone treatment or in combination with other agents like darolutamide, abiraterone acetate/prednisone, or apalutamide.

For conditions such as uterine fibroids and endometriosis, Relugolix is often studied as a combination therapy. One common formulation includes 40 mg of Relugolix along with 1 mg of estradiol and 0.5 mg of norethindrone acetate (Relugolix Combination therapy), typically taken daily. Some studies also explore a single 120 mg dose to assess its pharmacokinetics.

Side Effects

In clinical trials involving patients taking Relugolix, the most commonly reported side effect was hot flush.

Hot flush was experienced by 13.7% of patients taking Relugolix, compared to 6.4% on placebo.
Vaginal infection occurred in 7.6% of patients on Relugolix, versus 6.2% on placebo.
Vulvovaginal mycotic infection was reported by 7.6% of patients taking Relugolix, compared to 5.5% on placebo.
Urinary tract infection affected 5.7% of patients on Relugolix, versus 5.1% on placebo.
Vulvovaginal dryness was observed in 4.2% of patients taking Relugolix, compared to 3.3% on placebo.
Arthralgia (joint pain) occurred in 3.9% of patients on Relugolix, versus 3.1% on placebo.

Other side effects, such as headache (9.6% on Relugolix vs 10.7% on placebo), nasopharyngitis (6.7% on Relugolix vs 7.6% on placebo), hypertension (3.1% on Relugolix vs 3.8% on placebo), depressed mood (4.2% on Relugolix vs 5.5% on placebo), and upper respiratory tract infection (3.0% on Relugolix vs 4.3% on placebo), were reported at similar or lower rates in patients taking Relugolix compared to those on placebo.

Clinical Trial Results

Prostate Cancer

In studies of men with advanced prostate cancer, Relugolix demonstrated rapid and sustained testosterone suppression. In a Phase 3 study (NCT03085095), Relugolix achieved a castration rate (testosterone levels below 50 ng/dL) in 56.04% of patients by Day 4, compared to 0.00% for leuprolide acetate. By Day 15 (Week 3 Day 1), 98.71% of Relugolix patients achieved castration, versus 12.05% for leuprolide acetate. The sustained castration rate over the study period was 96.7% for Relugolix, compared to 88.8% for leuprolide acetate.

Relugolix also led to a faster and higher prostate-specific antigen (PSA) response. In the same study, the confirmed PSA response rate was 79.4% for Relugolix patients, compared to 19.8% for leuprolide acetate. For patients who discontinued treatment, testosterone recovery was significantly higher with Relugolix, with 53.93% to 93.01% of patients recovering testosterone levels, compared to 3.23% to 10.12% for leuprolide acetate. Additionally, Relugolix was associated with a lower rate of major adverse cardiovascular events (MACE) at 2.9%, compared to 6.2% for leuprolide acetate.

Another Phase 2 study (NCT02083185) further supported the rapid action of Relugolix, showing that patients taking either Relugolix 120 mg or Relugolix 80 mg achieved testosterone concentrations below 50 ng

Currently Recruiting Trials

Relugolix is currently being investigated in a variety of clinical trials, exploring its potential across different health conditions. These studies aim to understand how Relugolix works, its effectiveness, and its safety for patients. If you are interested in participating, you may find a study that aligns with your health needs.

The "Insights in Endocervical Mucus Secretion" study, NCT07111247, is a Phase 4 trial sponsored by Oregon Health and Science University. It is enrolling 15 participants to examine biological changes in endocervical mucus before and after taking oral Relugolix.
For women with moderate-to-severe endometriosis-associated pelvic pain, the University of Michigan is sponsoring a Phase 3 study, NCT07100782. This trial, with an enrollment target of 130 participants, seeks to understand how Relugolix Combination-Therapy affects pain, inflammation, and sensitivity.
In prostate cancer research, the University of Utah is conducting the "Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer" study, NCT07216248. This Phase 2 trial plans to enroll 160 patients with metastatic hormone-sensitive prostate cancer (mHSPC) to evaluate intermittent Relugolix combined with an androgen receptor pathway inhibitor.
Another important study for prostate cancer is the Phase 3 "REVELUTION-2" trial, NCT06650579, sponsored by Emory University. This study is comparing the cardiac impact of Relugolix plus abiraterone acetate versus leuprolide plus abiraterone acetate in 72 participants with advanced prostate cancer.
Qilu Pharmaceutical Co., Ltd. is sponsoring a Phase 3 study, NCT06671548, to assess the efficacy and safety of Relugolix in women experiencing heavy menstrual bleeding associated with uterine fibroids. This trial aims to enroll 120 women.
A large Phase 3B study, NCT05862272, sponsored by Sumitomo Pharma Switzerland GmbH, is evaluating bone mineral density changes with long-term use of Relugolix Combination Tablet. It targets 1000 women with uterine fibroids or endometriosis over 48 months.
Finally, the "Relugolix Pregnancy Registry," NCT05739123, is an observational study enrolling 728 pregnant women. Sponsored by Sumitomo Pharma Switzerland GmbH, it aims to collect data on maternal, fetal, and infant outcomes following exposure to Relugolix-containing therapy during pregnancy.

Where to Participate

Clinical trials for Relugolix are widely accessible, with research sites established across the United States. There are currently 446 sites in 306 cities across 42 states actively seeking participants. This broad reach helps ensure diverse populations can contribute to the understanding of Relugolix. The top cities with the most recruiting sites include:

New York, New York (9 sites)
Seattle, Washington (8 sites)
Philadelphia, Pennsylvania (8 sites)
St Louis, Missouri (8 sites)
Anchorage, Alaska (7 sites)
Atlanta, Georgia (6 sites)
Chicago, Illinois (6 sites)
Pittsburgh, Pennsylvania (6 sites)
Houston, Texas (5 sites)
Portland, Oregon (5 sites)

General eligibility for these trials is broad, welcoming participants aged 0 to 85 years, of all genders, including healthy volunteers and children, depending on the specific study criteria.

Development Timeline

The journey of Relugolix in clinical development began on March 11, 2014, with its first trial. Since then, it has progressed through a robust development pipeline, with the latest trial projected to conclude in March 2026. To date, a total of 53 trials have been initiated, enrolling over 19,403 participants across various phases. Early development saw Relugolix exploring conditions such as IBS-C and hyperphosphatemia. However, its potential quickly expanded, driven by key sponsors like Myovant Sciences GmbH and Sumitomo Pharma Switzerland GmbH. The pipeline significantly broadened to include a strong focus on prostate cancer, uterine fibroids, and endometriosis. Relugolix has been investigated across all phases, with 20 trials reaching Phase 3 and 18 trials in Phase 2, indicating significant progress towards potential approvals and widespread use. This expansion reflects a growing understanding of Relugolix's mechanism of action and its applicability to a diverse range of hormonal conditions.

Relugolix Development Timeline

Clinical trial activity from 2014 to 2026.

2026

NCT07455903PHASE2recruiting

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

50 enrolled

NCT07111247PHASE4recruiting

Insights in Endocervical Mucus Secretion

15 enrolled

2025

NCT07100782PHASE3recruiting

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

130 enrolled

NCT07302451PHASE2active not recruiting

REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)

50 enrolled

NCT07216248PHASE2recruiting

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

160 enrolled

NCT07025369PHASE2recruiting

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

30 enrolled

NCT06953076recruiting

Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study

111 enrolled

NCT05739136active not recruiting

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

530 enrolled

NCT06650579PHASE3recruiting

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

72 enrolled

2024

NCT06130995PHASE1recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

46 enrolled

NCT06463457PHASE2active not recruiting

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

33 enrolled

NCT06111313PHASE2recruiting

The University of Miami Adapt (UAdapt) Trial

130 enrolled

NCT06631521PHASE1recruiting

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

30 enrolled

NCT06499870PHASE2recruiting

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

50 enrolled

NCT06439524PHASE3recruiting

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

110 enrolled

NCT06330805PHASE2recruiting

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

70 enrolled

NCT06462014completed

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

507 enrolled

NCT07069465EARLY_PHASE1completed

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

10 enrolled

NCT06378866PHASE2recruiting

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

532 enrolled

NCT06312761PHASE1/PHASE2unknown

Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17

10 enrolled

NCT06279195PHASE2withdrawn

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

0 enrolled

NCT06397703PHASE2recruiting

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

392 enrolled

NCT06111781PHASE2recruiting

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

60 enrolled

NCT05765500PHASE2recruiting

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

110 enrolled

NCT06671548PHASE3recruiting

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

120 enrolled

2023

NCT06129851PHASE2not yet recruiting

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

90 enrolled

NCT05862272PHASE3recruiting

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

1,000 enrolled

NCT05739123recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

728 enrolled

NCT05679388PHASE1terminated

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

60 enrolled

NCT05605964PHASE3completed

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

387 enrolled

2022

NCT05467176active not recruiting

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

999 enrolled

NCT05320406PHASE2active not recruiting

RElugolix VErsus LeUprolide Cardiac Trial

94 enrolled

NCT05053152PHASE2active not recruiting

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

194 enrolled

2021

NCT05050084PHASE3active not recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

2,050 enrolled

NCT04787744PHASE2/PHASE3recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

464 enrolled

NCT04756037PHASE3completed

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

1,164 enrolled

NCT04666129PHASE1completed

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

48 enrolled

NCT04513717PHASE3active not recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

NCT04714554PHASE1completed

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

43 enrolled

2020

NCT04423211PHASE3recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

804 enrolled

NCT04523207PHASE2completed

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

108 enrolled

2018

NCT03751124PHASE3completed

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

229 enrolled

NCT03654274PHASE3completed

SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain

802 enrolled

2017

NCT03204318PHASE3completed

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

638 enrolled

NCT03204331PHASE3completed

SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

623 enrolled

NCT03412890PHASE3completed

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

477 enrolled

NCT03103087PHASE3completed

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

382 enrolled

NCT03049735PHASE3completed

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

388 enrolled

NCT03085095PHASE3completed

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

1,134 enrolled

2016

NCT04978688PHASE1completed

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

48 enrolled

NCT02655224PHASE3completed

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

65 enrolled

NCT02655237PHASE3completed

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

281 enrolled

2014

NCT02083185PHASE2completed

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

136 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Prostate Cancer	NCT07455903	Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT	recruiting	PHASE2	50
	NCT06463457	Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)	active not recruiting	PHASE2	33
	NCT06111313	The University of Miami Adapt (UAdapt) Trial	recruiting	PHASE2	130
	NCT06462014	Description of Relugolix Use in Patients With Prostate Cancer Within the VHA	completed	N/A	507
	NCT07069465	Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging	completed	EARLY_PHASE1	10
	NCT06397703	ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer	recruiting	PHASE2	392
	NCT06111781	The SUGAR Study; SBRT and Relugolix) for Prostate Cancer	recruiting	PHASE2	60
	NCT05765500	RecoverPC: Relugolix vs GnRH Agonist in Quality of Life	recruiting	PHASE2	110
	NCT05679388	A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients	terminated	PHASE1	60
	NCT05605964	Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate	completed	PHASE3	387
	NCT05467176	A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX	active not recruiting	N/A	999
	NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464
	NCT03085095	A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer	completed	PHASE3	1,134
	NCT02083185	A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer	completed	PHASE2	136
Prostate Adenocarcinoma	NCT07025369	Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial	recruiting	PHASE2	30
	NCT06499870	Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial	recruiting	PHASE2	50
	NCT06330805	Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer	recruiting	PHASE2	70
	NCT05679388	A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients	terminated	PHASE1	60
	NCT05053152	Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study	active not recruiting	PHASE2	194
	NCT05050084	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial	active not recruiting	PHASE3	2,050
	NCT04513717	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial	active not recruiting	PHASE3	2,753
	NCT04423211	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	recruiting	PHASE3	804
Stage III Prostate Cancer AJCC v8	NCT07025369	Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial	recruiting	PHASE2	30
	NCT06650579	REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial	recruiting	PHASE3	72
	NCT06129851	Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer	not yet recruiting	PHASE2	90
	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
	NCT04513717	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial	active not recruiting	PHASE3	2,753
Uterine Fibroids	NCT06671548	Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	recruiting	PHASE3	120
	NCT05862272	A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis	recruiting	PHASE3	1,000
	NCT03751124	Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	229
	NCT02655224	A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids	completed	PHASE3	65
	NCT02655237	A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids	completed	PHASE3	281
Heavy Menstrual Bleeding	NCT06671548	Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	recruiting	PHASE3	120
	NCT03412890	LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	477
	NCT03103087	LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	382
	NCT03049735	LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	388
Stage IIC Prostate Cancer AJCC v8	NCT07025369	Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial	recruiting	PHASE2	30
	NCT06330805	Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer	recruiting	PHASE2	70
	NCT06129851	Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer	not yet recruiting	PHASE2	90
	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Endometriosis	NCT07100782	Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain	recruiting	PHASE3	130
	NCT06439524	The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial	recruiting	PHASE3	110
	NCT05862272	A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis	recruiting	PHASE3	1,000
	NCT03654274	SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain	completed	PHASE3	802
Uterine Fibroid	NCT03412890	LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	477
	NCT03103087	LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	382
	NCT03049735	LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	388
Biochemically Recurrent Prostate Carcinoma	NCT06378866	Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial	recruiting	PHASE2	532
	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
	NCT04423211	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	recruiting	PHASE3	804
Pregnancy Complications	NCT05739136	MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy	active not recruiting	N/A	530
	NCT05739123	Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring	recruiting	N/A	728
Pelvic Pain	NCT07100782	Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain	recruiting	PHASE3	130
	NCT06279195	Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment	withdrawn	PHASE2	0
Prostatic Neoplasms	NCT05765500	RecoverPC: Relugolix vs GnRH Agonist in Quality of Life	recruiting	PHASE2	110
	NCT04523207	A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases	completed	PHASE2	108
Recurrent Prostate Cancer	NCT06378866	Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial	recruiting	PHASE2	532
	NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464
Stage IV Prostate Cancer AJCC v8	NCT07025369	Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial	recruiting	PHASE2	30
	NCT06129851	Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer	not yet recruiting	PHASE2	90
Stage IVA Prostate Cancer AJCC v8	NCT06650579	REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial	recruiting	PHASE3	72
	NCT04513717	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial	active not recruiting	PHASE3	2,753
Stage IVB Prostate Cancer AJCC v8	NCT05053152	Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study	active not recruiting	PHASE2	194
	NCT04423211	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	recruiting	PHASE3	804
Prostate Cancer (Adenocarcinoma)	NCT07302451	REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)	active not recruiting	PHASE2	50
	NCT06631521	Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer	recruiting	PHASE1	30
Localized Prostate Carcinoma	NCT07455903	Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT	recruiting	PHASE2	50
	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Endometriosis Related Pain	NCT03204318	SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain	completed	PHASE3	638
	NCT03204331	SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain	completed	PHASE3	623
Pregnancy Related	NCT05739136	MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy	active not recruiting	N/A	530
	NCT05739123	Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring	recruiting	N/A	728
Stage IIB Prostate Cancer AJCC v8	NCT06330805	Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer	recruiting	PHASE2	70
	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Pregnancy, High Risk	NCT05739136	MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy	active not recruiting	N/A	530
	NCT05739123	Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring	recruiting	N/A	728
Healthy	NCT04714554	A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men	completed	PHASE1	43
	NCT04978688	Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants	completed	PHASE1	48
Recurrent Castration-Sensitive Prostate Carcinoma	NCT06378866	Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial	recruiting	PHASE2	532
Recurrent Prostate Carcinoma	NCT06650579	REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial	recruiting	PHASE3	72
Stage I Prostate Cancer AJCC v8	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Stage II Prostate Cancer AJCC v8	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Stage IIA Prostate Cancer AJCC v8	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Stage IIIA Prostate Cancer AJCC v8	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Stage IIIB Prostate Cancer AJCC v8	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Stage IIIC Prostate Cancer AJCC v8	NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94
Uterine Bleeding	NCT06953076	Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study	recruiting	N/A	111
Uterine Hemorrhage	NCT06953076	Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study	recruiting	N/A	111
Uterine Leiomyoma	NCT03751124	Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	229
Uterine Leiomyomas	NCT06953076	Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study	recruiting	N/A	111
Uterine Neoplasms	NCT06953076	Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study	recruiting	N/A	111
Prostate CA	NCT06631521	Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer	recruiting	PHASE1	30
Androgen Deprivation Therapy	NCT06130995	Relugolix + Enzalutamide Study in High-Risk Prostate Cancer	recruiting	PHASE1	46
Castration-resistant Prostate Cancer	NCT06378866	Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial	recruiting	PHASE2	532
Cervical Mucus	NCT07111247	Insights in Endocervical Mucus Secretion	recruiting	PHASE4	15
Contraception	NCT04756037	Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy	completed	PHASE3	1,164
De Novo Prostate Cancer	NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464
Hormone Sensitive Prostate Cancer	NCT06463457	Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)	active not recruiting	PHASE2	33
Hypogonadism, Male	NCT06312761	Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17	unknown	PHASE1/PHASE2	10
Locally Advanced Prostate Cancer	NCT06130995	Relugolix + Enzalutamide Study in High-Risk Prostate Cancer	recruiting	PHASE1	46
Metastatic Castration-Resistant Prostate Cancer	NCT04666129	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer	completed	PHASE1	48
Metastatic Castration-Sensitive Prostate Cancer	NCT04666129	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer	completed	PHASE1	48
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)	NCT07216248	Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer	recruiting	PHASE2	160
Metastatic Prostate Cancer	NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464
Metastatic Prostate Carcinoma	NCT04423211	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	recruiting	PHASE3	804
Non-Metastatic Castration-Resistant Prostate Cancer	NCT04666129	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer	completed	PHASE1	48
Oligometastasis	NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464
Oligometastatic Prostate Carcinoma	NCT05053152	Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study	active not recruiting	PHASE2	194
Oligorecurrence	NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464
Advanced Prostate Cancer	NCT06463457	Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)	active not recruiting	PHASE2	33
Prostate Cancer Metastatic	NCT05679388	A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients	terminated	PHASE1	60
Prostate Cancer Surgery	NCT06631521	Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer	recruiting	PHASE1	30
Prostate Ductal Adenocarcinoma	NCT05053152	Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study	active not recruiting	PHASE2	194
Prostate Intraductal Carcinoma	NCT05053152	Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study	active not recruiting	PHASE2	194

All Relugolix Clinical Trials (53)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07455903	Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT	recruiting	PHASE2	50	Baptist Health South Florida
NCT07111247	Insights in Endocervical Mucus Secretion	recruiting	PHASE4	15	Oregon Health and Science University
NCT07100782	Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain	recruiting	PHASE3	130	University of Michigan
NCT07302451	REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)	active not recruiting	PHASE2	50	National Cancer Institute, Naples
NCT07216248	Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer	recruiting	PHASE2	160	University of Utah
NCT07025369	Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial	recruiting	PHASE2	30	Mayo Clinic
NCT06953076	Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study	recruiting	N/A	111	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NCT05739136	MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy	active not recruiting	N/A	530	Sumitomo Pharma Switzerland GmbH
NCT06650579	REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial	recruiting	PHASE3	72	Emory University
NCT06130995	Relugolix + Enzalutamide Study in High-Risk Prostate Cancer	recruiting	PHASE1	46	University of Oklahoma
NCT06463457	Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)	active not recruiting	PHASE2	33	Atish Choudhury, MD
NCT06111313	The University of Miami Adapt (UAdapt) Trial	recruiting	PHASE2	130	University of Miami
NCT06631521	Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer	recruiting	PHASE1	30	AdventHealth
NCT06499870	Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial	recruiting	PHASE2	50	Sean Sachdev
NCT06439524	The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial	recruiting	PHASE3	110	Main Line Health
NCT06330805	Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer	recruiting	PHASE2	70	Ohio State University Comprehensive Cancer Center
NCT06462014	Description of Relugolix Use in Patients With Prostate Cancer Within the VHA	completed	N/A	507	Pfizer
NCT07069465	Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging	completed	EARLY_PHASE1	10	Urology Clinics of North Texas
NCT06378866	Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial	recruiting	PHASE2	532	Mayo Clinic
NCT06312761	Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17	unknown	PHASE1/PHASE2	10	University of Washington
NCT06279195	Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment	withdrawn	PHASE2	0	Endeavor Health
NCT06397703	ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer	recruiting	PHASE2	392	NYU Langone Health
NCT06111781	The SUGAR Study; SBRT and Relugolix) for Prostate Cancer	recruiting	PHASE2	60	Yale University
NCT05765500	RecoverPC: Relugolix vs GnRH Agonist in Quality of Life	recruiting	PHASE2	110	Dana-Farber Cancer Institute
NCT06671548	Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	recruiting	PHASE3	120	Qilu Pharmaceutical Co., Ltd.
NCT06129851	Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer	not yet recruiting	PHASE2	90	University of Kansas Medical Center
NCT05862272	A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis	recruiting	PHASE3	1,000	Sumitomo Pharma Switzerland GmbH
NCT05739123	Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring	recruiting	N/A	728	Sumitomo Pharma Switzerland GmbH
NCT05679388	A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients	terminated	PHASE1	60	University of Chicago
NCT05605964	Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate	completed	PHASE3	387	Sumitomo Pharma America, Inc.
NCT05467176	A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX	active not recruiting	N/A	999	Sumitomo Pharma America, Inc.
NCT05320406	RElugolix VErsus LeUprolide Cardiac Trial	active not recruiting	PHASE2	94	Emory University
NCT05053152	Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study	active not recruiting	PHASE2	194	NRG Oncology
NCT05050084	Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial	active not recruiting	PHASE3	2,050	NRG Oncology
NCT04787744	Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer	recruiting	PHASE2/PHASE3	464	VA Office of Research and Development
NCT04756037	Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy	completed	PHASE3	1,164	Sumitomo Pharma Switzerland GmbH
NCT04666129	Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer	completed	PHASE1	48	Sumitomo Pharma America, Inc.
NCT04513717	Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial	active not recruiting	PHASE3	2,753	NRG Oncology
NCT04714554	A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men	completed	PHASE1	43	Myovant Sciences GmbH
NCT04423211	Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging	recruiting	PHASE3	804	ECOG-ACRIN Cancer Research Group
NCT04523207	A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases	completed	PHASE2	108	Janssen Research & Development, LLC
NCT03751124	Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	229	Myovant Sciences GmbH
NCT03654274	SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain	completed	PHASE3	802	Myovant Sciences GmbH
NCT03204318	SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain	completed	PHASE3	638	Myovant Sciences GmbH
NCT03204331	SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain	completed	PHASE3	623	Myovant Sciences GmbH
NCT03412890	LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	477	Myovant Sciences GmbH
NCT03103087	LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	382	Myovant Sciences GmbH
NCT03049735	LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	completed	PHASE3	388	Myovant Sciences GmbH
NCT03085095	A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer	completed	PHASE3	1,134	Myovant Sciences GmbH
NCT04978688	Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants	completed	PHASE1	48	Myovant Sciences GmbH
NCT02655224	A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids	completed	PHASE3	65	Takeda
NCT02655237	A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids	completed	PHASE3	281	Takeda
NCT02083185	A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer	completed	PHASE2	136	Millennium Pharmaceuticals, Inc.

Where to Participate: All Relugolix Trial Sites in the U.S. (439 sites across 41 states)

Every actively recruiting Relugolixtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Mobile	Mobile36604	NCT05862272	Map
AK	Alaska Breast Care and Surgery LLC	Anchorage99508	NCT04423211	Map
AK	Alaska Oncology and Hematology LLC	Anchorage99508	NCT04423211	Map
AK	Alaska Women's Cancer Care	Anchorage99508	NCT04423211	Map
AK	Anchorage Associates in Radiation Medicine	Anchorage98508	NCT04423211	Map
AK	Katmai Oncology Group	Anchorage99508	NCT04423211	Map
AK	Providence Alaska Medical Center	Anchorage99508	NCT04423211	Map
AZ	Chandler	Chandler85224	NCT05862272	Map
AZ	Mesa	Mesa85209	NCT05862272	Map
AZ	Peoria	Peoria85381	NCT05862272	Map
AZ	Cancer Center at Saint Joseph's	Phoenix85004	NCT04423211	Map
AZ	Mayo Clinic in Arizona	Phoenix85054	NCT06378866	Map
AZ	Phoenix	Phoenix85018	NCT05862272	Map
AZ	Mayo Clinic in Arizona	Scottsdale85259	NCT07025369	Map
AZ	Tucson	Tucson85715-3834	NCT05862272	Map
AR	Mercy Hospital Fort Smith	Fort Smith72903	NCT04423211	Map
CA	Mission Hope Medical Oncology - Arroyo Grande	Arroyo Grande93420	NCT04423211	Map
CA	Burbank	Burbank91506-1773	NCT05862272	Map
CA	Providence Saint Joseph Medical Center/Disney Family Cancer Center	Burbank91505	NCT04423211	Map
CA	Canoga Park	Canoga Park91303	NCT05862272	Map
CA	Mercy Cancer Center - Carmichael	Carmichael95608	NCT04423211	Map
CA	Mercy San Juan Medical Center	Carmichael95608	NCT04423211	Map
CA	City of Hope Corona	Corona92882	NCT04423211	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT04423211	Map
CA	Mercy Cancer Center - Elk Grove	Elk Grove95758	NCT04423211	Map
CA	Encinitas	Encinitas92024-1329	NCT05862272	Map
CA	UC San Diego Health System - Encinitas	Encinitas92024	NCT04423211	Map
CA	Inglewood	Inglewood90301	NCT05862272	Map
CA	UC San Diego Moores Cancer Center	La Jolla92093	NCT04423211	Map
CA	City of Hope Antelope Valley	Lancaster93534	NCT04423211	Map
CA	Lomita	Lomita90717-2101	NCT05862272	Map
CA	Long Beach	Long Beach90805-4587	NCT05862272	Map
CA	VA Long Beach Healthcare System, Long Beach, CA	Long Beach90822	NCT04787744	Map
CA	Los Angeles	Los Angeles90036	NCT05862272	Map
CA	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles90095	NCT04423211	Map
CA	Mercy Cancer Center - Rocklin	Rocklin95765	NCT04423211	Map
CA	Mercy Cancer Center - Sacramento	Sacramento95816	NCT04423211	Map
CA	Sacramento	Sacramento95817-2307	NCT05862272	Map
CA	UC San Diego Medical Center - Hillcrest	San Diego92103	NCT04423211	Map
CA	San Fernando	San Fernando91340-4199	NCT05862272	Map
CA	Pacific Central Coast Health Center-San Luis Obispo	San Luis Obispo93401	NCT04423211	Map
CA	Mission Hope Medical Oncology - Santa Maria	Santa Maria93444	NCT04423211	Map
CA	City of Hope South Pasadena	South Pasadena91030	NCT04423211	Map
CA	Stanford	Stanford94305-2200	NCT05862272	Map
CA	Saint Joseph's Medical Center	Stockton95204	NCT04423211	Map
CA	City of Hope Upland	Upland91786	NCT04423211	Map
CA	Valley Village	Valley Village91607	NCT05862272	Map
CA	VA Greater Los Angeles Healthcare System, West Los Angeles, CA	West Los Angeles90073	NCT04787744	Map
CA	Woodland Memorial Hospital	Woodland95695	NCT04423211	Map
CO	Aurora	Aurora80045-2517	NCT05862272	Map
CO	Penrose-Saint Francis Healthcare	Colorado Springs80907	NCT04423211	Map
CO	Rocky Mountain Cancer Centers-Penrose	Colorado Springs80907	NCT04423211	Map
CO	Saint Francis Cancer Center	Colorado Springs80923	NCT04423211	Map
CO	Dillon Health Center/Shaw Cancer Center	Dillon80435	NCT04423211	Map
CO	Shaw Cancer Center	Edwards81632	NCT04423211	Map
CO	Greenwood Village	Greenwood Village80111	NCT05862272	Map
CO	Lakewood	Lakewood80228	NCT05862272	Map
CO	Saint Anthony Hospital	Lakewood80228	NCT04423211	Map
CO	Longmont United Hospital	Longmont80501	NCT04423211	Map
CO	Saint Mary Corwin Medical Center	Pueblo81004	NCT04423211	Map
CO	Saint Anthony North Hospital	Westminster80023	NCT04423211	Map
CT	Yale Cancer Center	New Haven06520	NCT06111781	Map
DC	Sibley Memorial Hospital	Washington D.C.20016	NCT04423211	Map
DC	Washington	Washington D.C.02011	NCT05862272	Map
DC	Washington DC VA Medical Center, Washington, DC	Washington D.C.20422-0001	NCT04787744	Map
FL	Aventura	Aventura33180	NCT05862272	Map
FL	Bay Pines VA Healthcare System, Pay Pines, FL	Bay Pines33744	NCT04787744	Map
FL	Deland	DeLand32720	NCT05862272	Map
FL	Hialeah	Hialeah33016	NCT05862272	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06378866	Map
FL	Kissimmee	Kissimmee34741-2358	NCT05862272	Map
FL	Lake Worth	Lake Worth33461	NCT05862272	Map
FL	Margate	Margate33063-5715	NCT05862272	Map
FL	Miami	Miami33126	NCT05862272	Map
FL	Miami	Miami33155	NCT05862272	Map
FL	Miami	Miami33173	NCT05862272	Map
FL	Miami Cancer Institute at Baptist Health, Inc.	Miami33176	NCT07455903	Map
FL	University of Miami	Miami33136	NCT06111313	Map
FL	Miami Beach	Miami Beach33140	NCT05862272	Map
FL	Miami Springs	Miami Springs33166	NCT05862272	Map
FL	New Port Richey	New Port Richey34652-4020	NCT05862272	Map
FL	New Port Richey	New Port Richey34652	NCT05862272	Map
FL	AdventHealth Orlando	Orlando32803	NCT06631521	Map
FL	Orlando	Orlando32808	NCT05862272	Map
FL	Orlando	Orlando32819	NCT05862272	Map
FL	Panama City	Panama City32405	NCT05862272	Map
FL	Sarasota	Sarasota34239	NCT05862272	Map
FL	Tamarac	Tamarac33321	NCT05862272	Map
FL	Moffitt Cancer Center	Tampa33612	NCT04423211	Map
FL	Moffitt Cancer Center - McKinley Campus	Tampa33612	NCT04423211	Map
FL	Moffitt Cancer Center-International Plaza	Tampa33607	NCT04423211	Map
FL	Tampa	Tampa33614-1874	NCT05862272	Map
FL	Venice	Venice34285	NCT05862272	Map
FL	Moffitt Cancer Center at Wesley Chapel	Wesley Chapel33544	NCT04423211	Map
FL	West Palm Beach	West Palm Beach33409	NCT05862272	Map
GA	Atlanta	Atlanta30342	NCT05862272	Map
GA	Atlanta	Atlanta30363	NCT05862272	Map
GA	Emory Proton Therapy Center	Atlanta30308	NCT06650579	Map
GA	Emory Saint Joseph's Hospital	Atlanta30342	NCT06650579	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT06650579	Map
GA	Winship at Emory Midtown	Atlanta30308	NCT06650579	Map
GA	College Park	College Park30349-3103	NCT05862272	Map
GA	Fayetteville	Fayetteville31204	NCT05862272	Map
GA	Norcross	Norcross30093	NCT05862272	Map
ID	Saint Luke's Cancer Institute - Boise	Boise83712	NCT04423211	Map
ID	Kootenai Health - Coeur d'Alene	Coeur d'Alene83814	NCT04423211	Map
ID	Saint Luke's Cancer Institute - Fruitland	Fruitland83619	NCT04423211	Map
ID	Idaho Falls	Idaho Falls83404-8322	NCT05862272	Map
ID	Idaho Falls	Idaho Falls83404	NCT05862272	Map
ID	Meridian	Meridian83646	NCT05862272	Map
ID	Saint Luke's Cancer Institute - Meridian	Meridian83642	NCT04423211	Map
ID	Saint Luke's Cancer Institute - Nampa	Nampa83687	NCT04423211	Map
ID	Kootenai Clinic Cancer Services - Post Falls	Post Falls83854	NCT04423211	Map
ID	Saint Luke's Cancer Institute - Twin Falls	Twin Falls83301	NCT04423211	Map
IL	Alton Memorial Hospital	Alton62002	NCT04423211	Map
IL	OSF Saint Anthony's Health Center	Alton62002	NCT04423211	Map
IL	Rush-Copley Medical Center	Aurora60504	NCT04423211	Map
IL	Illinois CancerCare-Bloomington	Bloomington61704	NCT04423211	Map
IL	Illinois CancerCare-Canton	Canton61520	NCT04423211	Map
IL	Memorial Hospital of Carbondale	Carbondale62902	NCT04423211	Map
IL	SIH Cancer Institute	Carterville62918	NCT04423211	Map
IL	Illinois CancerCare-Carthage	Carthage62321	NCT04423211	Map
IL	Centralia Oncology Clinic	Centralia62801	NCT04423211	Map
IL	Chicago	Chicago60607-4911	NCT05862272	Map
IL	Chicago	Chicago60616	NCT05862272	Map
IL	Northwestern University	Chicago60611	NCT04423211	Map
IL	Northwestern University	Chicago60611	NCT06499870	Map
IL	Rush MD Anderson Cancer Center	Chicago60612	NCT04423211	Map
IL	University of Illinois	Chicago60612	NCT04423211	Map
IL	Carle at The Riverfront	Danville61832	NCT04423211	Map
IL	Cancer Care Specialists of Illinois - Decatur	Decatur62526	NCT04423211	Map
IL	Decatur Memorial Hospital	Decatur62526	NCT04423211	Map
IL	Northwestern Medicine Cancer Center Kishwaukee	DeKalb60115	NCT04423211	Map
IL	Carle Physician Group-Effingham	Effingham62401	NCT04423211	Map
IL	Crossroads Cancer Center	Effingham62401	NCT04423211	Map
IL	Illinois CancerCare-Eureka	Eureka61530	NCT04423211	Map
IL	Illinois CancerCare-Galesburg	Galesburg61401	NCT04423211	Map
IL	Northwestern Medicine Cancer Center Delnor	Geneva60134	NCT04423211	Map
IL	Edward Hines Jr. VA Hospital, Hines, IL	Hines60141-3030	NCT04787744	Map
IL	Illinois CancerCare-Kewanee Clinic	Kewanee61443	NCT04423211	Map
IL	Rush MD Anderson Cancer Center at Rush Lisle	Lisle60532	NCT04423211	Map
IL	Illinois CancerCare-Macomb	Macomb61455	NCT04423211	Map
IL	Carle Physician Group-Mattoon/Charleston	Mattoon61938	NCT04423211	Map
IL	SSM Health Good Samaritan	Mount Vernon62864	NCT04423211	Map
IL	Cancer Care Center of O'Fallon	O'Fallon62269	NCT04423211	Map
IL	HSHS Saint Elizabeth's Hospital	O'Fallon62269	NCT04423211	Map
IL	Northwestern Medicine Oak Brook	Oak Brook60523	NCT04423211	Map
IL	Rush MD Anderson Cancer Center at Rush Oak Park	Oak Park60304	NCT04423211	Map
IL	Illinois CancerCare-Ottawa Clinic	Ottawa61350	NCT04423211	Map
IL	Illinois CancerCare-Pekin	Pekin61554	NCT04423211	Map
IL	Illinois CancerCare-Peoria	Peoria61615	NCT04423211	Map
IL	Methodist Medical Center of Illinois	Peoria61636	NCT04423211	Map
IL	Illinois CancerCare-Peru	Peru61354	NCT04423211	Map
IL	Illinois CancerCare-Princeton	Princeton61356	NCT04423211	Map
IL	UW Health Carbone Cancer Center Rockford	Rockford61114	NCT04423211	Map
IL	Schaumburg	Schaumburg60173-5831	NCT05862272	Map
IL	Southern Illinois University School of Medicine	Springfield62702	NCT04423211	Map
IL	Springfield Clinic	Springfield62702	NCT04423211	Map
IL	Springfield Memorial Hospital	Springfield62781	NCT04423211	Map
IL	Carle Cancer Center	Urbana61801	NCT04423211	Map
IL	The Carle Foundation Hospital	Urbana61801	NCT04423211	Map
IL	Northwestern Medicine Cancer Center Warrenville	Warrenville60555	NCT04423211	Map
IL	Illinois CancerCare - Washington	Washington61571	NCT04423211	Map
IN	Richard L. Roudebush VA Medical Center, Indianapolis, IN	Indianapolis46202-2884	NCT04787744	Map
IA	Mercy Hospital	Cedar Rapids52403	NCT04423211	Map
IA	Oncology Associates at Mercy Medical Center	Cedar Rapids52403	NCT04423211	Map
KS	Central Care Cancer Center - Garden City	Garden City67846	NCT04423211	Map
KS	Lenexa	Lenexa66215-2733	NCT05862272	Map
KS	Mercy Hospital Pittsburg	Pittsburg66762	NCT04423211	Map
KS	Wichita	Wichita67211	NCT05862272	Map
KY	Saint Joseph Hospital	Lexington40504	NCT04423211	Map
KY	Saint Joseph Hospital East	Lexington40509	NCT04423211	Map
KY	Saint Joseph Radiation Oncology Resource Center	Lexington40504	NCT04423211	Map
LA	LSU Health Baton Rouge-North Clinic	Baton Rouge70805	NCT04423211	Map
LA	Our Lady of the Lake Physician Group	Baton Rouge70808	NCT04423211	Map
LA	Covington	Covington70433	NCT05862272	Map
LA	Marrero	Marrero70072	NCT05862272	Map
LA	Metairie	Metairie70001	NCT05862272	Map
LA	New Orleans	New Orleans70115-6235	NCT05862272	Map
LA	New Orleans	New Orleans70127	NCT05862272	Map
LA	Slidell	Slidell70458-2004	NCT05862272	Map
MD	Baltimore	Baltimore21205	NCT05862272	Map
MD	Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD	Baltimore21201	NCT04787744	Map
MD	Johns Hopkins University/Sidney Kimmel Cancer Center	Baltimore21287	NCT04423211	Map
MD	Suburban Hospital	Bethesda20814	NCT04423211	Map
MD	Laurel	Laurel20707-5203	NCT05862272	Map
MD	Towson	Towson21204	NCT05862272	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT05765500	Map
MA	VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA	Boston02130	NCT04787744	Map
MA	Dana-Farber Cancer Institute at Foxborough	Foxborough02035	NCT05765500	Map
MI	University of Michigan	Ann Arbor48109	NCT07100782	Map
MI	VA Ann Arbor Healthcare System, Ann Arbor, MI	Ann Arbor48105	NCT04787744	Map
MI	Bay City	Bay City48706	NCT05862272	Map
MI	Dearborn Heights	Dearborn Heights48127	NCT05862272	Map
MI	Detroit	Detroit48201	NCT05862272	Map
MN	Minnesota Oncology - Burnsville	Burnsville55337	NCT04423211	Map
MN	Minnesota Oncology Hematology PA-Chaska	Chaska55318	NCT04423211	Map
MN	Mercy Hospital	Coon Rapids55433	NCT04423211	Map
MN	Minnesota Oncology - Coon Rapids	Coon Rapids55433	NCT04423211	Map
MN	Fairview Southdale Hospital	Edina55435	NCT04423211	Map
MN	Minnesota Oncology - Edina	Edina55435	NCT04423211	Map
MN	Fairview Clinics and Surgery Center Maple Grove	Maple Grove55369	NCT04423211	Map
MN	Minnesota Oncology - Maple Grove	Maple Grove55369	NCT04423211	Map
MN	Minnesota Oncology Hematology PA-Maplewood	Maplewood55109	NCT04423211	Map
MN	Saint John's Hospital - Healtheast	Maplewood55109	NCT04423211	Map
MN	Abbott-Northwestern Hospital	Minneapolis55407	NCT04423211	Map
MN	Health Partners Inc	Minneapolis55454	NCT04423211	Map
MN	Hennepin County Medical Center	Minneapolis55415	NCT04423211	Map
MN	Monticello Cancer Center	Monticello55362	NCT04423211	Map
MN	North Memorial Medical Health Center	Robbinsdale55422	NCT04423211	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06378866	Map
MN	Coborn Cancer Center at Saint Cloud Hospital	Saint Cloud56303	NCT04423211	Map
MN	Park Nicollet Clinic - Saint Louis Park	Saint Louis Park55416	NCT04423211	Map
MN	Regions Hospital	Saint Paul55101	NCT04423211	Map
MN	United Hospital	Saint Paul55102	NCT04423211	Map
MN	Saint Francis Regional Medical Center	Shakopee55379	NCT04423211	Map
MN	Lakeview Hospital	Stillwater55082	NCT04423211	Map
MN	Ridgeview Medical Center	Waconia55387	NCT04423211	Map
MN	Rice Memorial Hospital	Willmar56201	NCT04423211	Map
MN	Minnesota Oncology Hematology PA-Woodbury	Woodbury55125	NCT04423211	Map
MS	Baptist Cancer Center-Grenada	Grenada38901	NCT04423211	Map
MS	Baptist Memorial Hospital and Cancer Center-Union County	New Albany38652	NCT04423211	Map
MS	Baptist Memorial Hospital and Cancer Center-Oxford	Oxford38655	NCT04423211	Map
MS	Ridgeland	Ridgeland39157-5179	NCT05862272	Map
MO	Central Care Cancer Center - Bolivar	Bolivar65613	NCT04423211	Map
MO	Mercy Cancer Center - Cape Girardeau	Cape Girardeau63703	NCT04423211	Map
MO	Saint Francis Medical Center	Cape Girardeau63703	NCT04423211	Map
MO	Siteman Cancer Center at Saint Peters Hospital	City of Saint Peters63376	NCT04423211	Map
MO	Siteman Cancer Center at West County Hospital	Creve Coeur63141	NCT04423211	Map
MO	Parkland Health Center - Farmington	Farmington63640	NCT04423211	Map
MO	Freeman Health System	Joplin64804	NCT04423211	Map
MO	Mercy Hospital Joplin	Joplin64804	NCT04423211	Map
MO	Lake Regional Hospital	Osage Beach65065	NCT04423211	Map
MO	Mercy Clinic-Rolla-Cancer and Hematology	Rolla65401	NCT04423211	Map
MO	Phelps Health Delbert Day Cancer Institute	Rolla65401	NCT04423211	Map
MO	Heartland Regional Medical Center	Saint Joseph64506	NCT04423211	Map
MO	Sainte Genevieve County Memorial Hospital	Sainte Genevieve63670	NCT04423211	Map
MO	CoxHealth South Hospital	Springfield65807	NCT04423211	Map
MO	Mercy Hospital Springfield	Springfield65804	NCT04423211	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT04423211	Map
MO	Mercy Hospital South	St Louis63128	NCT04423211	Map
MO	Missouri Baptist Medical Center	St Louis63131	NCT04423211	Map
MO	Saint Louis	St Louis63108-1495	NCT05862272	Map
MO	Siteman Cancer Center at Christian Hospital	St Louis63136	NCT04423211	Map
MO	Siteman Cancer Center-South County	St Louis63129	NCT04423211	Map
MO	St Louis	St Louis63141	NCT05862272	Map
MO	Washington University School of Medicine	St Louis63110	NCT04423211	Map
MO	Missouri Baptist Sullivan Hospital	Sullivan63080	NCT04423211	Map
MO	BJC Outpatient Center at Sunset Hills	Sunset Hills63127	NCT04423211	Map
MT	Billings Clinic Cancer Center	Billings59101	NCT04423211	Map
MT	Bozeman Health Deaconess Hospital	Bozeman59715	NCT04423211	Map
MT	Benefis Sletten Cancer Institute	Great Falls59405	NCT04423211	Map
MT	Great Falls Clinic	Great Falls59405	NCT04423211	Map
MT	Hi-Line Sletten Cancer Center	Havre59501	NCT04423211	Map
MT	Logan Health Medical Center	Kalispell59901	NCT04423211	Map
MT	Community Medical Center	Missoula59804	NCT04423211	Map
MT	Saint Patrick Hospital - Community Hospital	Missoula59802	NCT04423211	Map
NE	Grand Island	Grand Island68803-4327	NCT05862272	Map
NE	CHI Health Good Samaritan	Kearney68847	NCT04423211	Map
NE	Norfolk	Norfolk68701	NCT05862272	Map
NE	Alegent Health Bergan Mercy Medical Center	Omaha68124	NCT04423211	Map
NE	Creighton University Medical Center	Omaha68131	NCT04423211	Map
NV	Las Vegas	Las Vegas89109	NCT05862272	Map
NV	North Las Vegas	North Las Vegas89030	NCT05862272	Map
NJ	Cooper Hospital University Medical Center	Camden08103	NCT04423211	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT04423211	Map
NJ	Robert Wood Johnson University Hospital Somerset	Somerville08876	NCT04423211	Map
NJ	Community Medical Center	Toms River08755	NCT04423211	Map
NJ	MD Anderson Cancer Center at Cooper-Voorhees	Voorhees Township08043	NCT04423211	Map
NJ	West New York	West New York07093-2622	NCT05862272	Map
NY	Northwell Health Imbert Cancer Center	Bay Shore11706	NCT04423211	Map
NY	Northwell Health Physicians Partners Radiation Medicine at Queens	Forest Hills11375	NCT04423211	Map
NY	Northwell Health/Center for Advanced Medicine	Lake Success11042	NCT04423211	Map
NY	Lenox Hill Hospital	New York10075	NCT04423211	Map
NY	Manhattan Eye Ear and Throat Hospital	New York10065	NCT04423211	Map
NY	Memorial Sloan Kettering Cancer Center	New York10017	NCT06111781	Map
NY	Mount Sinai Chelsea	New York10011	NCT04423211	Map
NY	Mount Sinai Hospital	New York10029	NCT04423211	Map
NY	Mount Sinai Union Square	New York10003	NCT04423211	Map
NY	Mount Sinai West	New York10019	NCT04423211	Map
NY	New York Proton Center	New York10035	NCT04423211	Map
NY	NYU Langone Health	New York10016	NCT06397703	Map
NY	Queens Cancer Center	Rego Park11374	NCT04423211	Map
NY	Phelps Memorial Hospital Center	Sleepy Hollow10591	NCT04423211	Map
NY	Stony Brook University Medical Center	Stony Brook11794	NCT04423211	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT04423211	Map
NY	Montefiore Medical Center-Einstein Campus	The Bronx10461	NCT04423211	Map
NY	Montefiore Medical Center-Weiler Hospital	The Bronx10461	NCT04423211	Map
NY	Westchester Medical Center	Valhalla10595	NCT04423211	Map
NC	Durham	Durham27713	NCT05862272	Map
NC	Durham VA Medical Center, Durham, NC	Durham27705	NCT04787744	Map
NC	ECU Health Oncology Kinston	Kinston28501	NCT04423211	Map
NC	New Bern	New Bern28562	NCT05862272	Map
NC	Raleigh	Raleigh27607	NCT05862272	Map
NC	Raleigh	Raleigh27612-8104	NCT05862272	Map
NC	PPD	Wilmington28401	NCT05739123	Map
NC	Winston Salem	Winston-Salem27103-1749	NCT05862272	Map
OH	Bethesda North Hospital	Cincinnati45242	NCT04423211	Map
OH	Cincinnati	Cincinnati45255	NCT05862272	Map
OH	Good Samaritan Hospital - Cincinnati	Cincinnati45220	NCT04423211	Map
OH	Cleveland	Cleveland44124	NCT05862272	Map
OH	Louis Stokes VA Medical Center, Cleveland, OH	Cleveland44106	NCT04787744	Map
OH	Columbus	Columbus43213	NCT05862272	Map
OH	Columbus	Columbus43231	NCT05862272	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT04423211	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06330805	Map
OH	Dublin	Dublin43016	NCT05862272	Map
OH	Englewood	Englewood45322	NCT05862272	Map
OH	Middletown	Middletown45005-2593	NCT05862272	Map
OK	Mercy Hospital Oklahoma City	Oklahoma City73120	NCT04423211	Map
OK	Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC)	Oklahoma City73104	NCT06130995	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT04423211	Map
OR	Saint Charles Health System	Bend97701	NCT04423211	Map
OR	Clackamas Radiation Oncology Center	Clackamas97015	NCT04423211	Map
OR	Bay Area Hospital	Coos Bay97420	NCT04423211	Map
OR	Providence Newberg Medical Center	Newberg97132	NCT04423211	Map
OR	Providence Willamette Falls Medical Center	Oregon City97045	NCT04423211	Map
OR	Oregon Health & Science University	Portland97239	NCT07111247	Map
OR	Oregon Health and Science University	Portland97239	NCT04423211	Map
OR	Providence Portland Medical Center	Portland97213	NCT04423211	Map
OR	Providence Saint Vincent Medical Center	Portland97225	NCT04423211	Map
PA	UPMC Altoona	Altoona16601	NCT04423211	Map
PA	UPMC-Heritage Valley Health System Beaver	Beaver15009	NCT04423211	Map
PA	Carlisle Regional Cancer Center	Carlisle17015	NCT04423211	Map
PA	Erie	Erie16507-1423	NCT05862272	Map
PA	UPMC Hillman Cancer Center Erie	Erie16505	NCT04423211	Map
PA	UPMC Cancer Center at UPMC Horizon	Farrell16121	NCT04423211	Map
PA	UPMC Cancer Centers - Arnold Palmer Pavilion	Greensburg15601	NCT04423211	Map
PA	UPMC Pinnacle Cancer Center/Community Osteopathic Campus	Harrisburg17109	NCT04423211	Map
PA	Penn State Milton S Hershey Medical Center	Hershey17033-0850	NCT04423211	Map
PA	UPMC-Johnstown/John P. Murtha Regional Cancer Center	Johnstown15901	NCT04423211	Map
PA	UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion	Mechanicsburg17050	NCT04423211	Map
PA	UPMC Cancer Center - Monroeville	Monroeville15146	NCT04423211	Map
PA	UPMC Hillman Cancer Center in Coraopolis	Moon Township15108	NCT04423211	Map
PA	UPMC Cancer Center-Natrona Heights	Natrona Heights15065	NCT04423211	Map
PA	UPMC Hillman Cancer Center - New Castle	New Castle16105	NCT04423211	Map
PA	Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA	Philadelphia19104-4551	NCT04787744	Map
PA	Penn Presbyterian Medical Center	Philadelphia19104	NCT04423211	Map
PA	Philadelphia	Philadelphia19104	NCT05862272	Map
PA	Philadelphia	Philadelphia19114	NCT05862272	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT04423211	Map
PA	University of Pennsylvania/Abramson Cancer Center	Philadelphia19104	NCT04423211	Map
PA	University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh15232	NCT04423211	Map
PA	UPMC-Magee Womens Hospital	Pittsburgh15213	NCT04423211	Map
PA	UPMC-Passavant Hospital	Pittsburgh15237	NCT04423211	Map
PA	UPMC-Saint Clair Hospital Cancer Center	Pittsburgh15243	NCT04423211	Map
PA	UPMC-Saint Margaret	Pittsburgh15215	NCT04423211	Map
PA	UPMC-Shadyside Hospital	Pittsburgh15232	NCT04423211	Map
PA	UPMC Cancer Center at UPMC Northwest	Seneca16346	NCT04423211	Map
PA	UPMC Cancer Center-Uniontown	Uniontown15401	NCT04423211	Map
PA	UPMC Uniontown Hospital Radiation Oncology	Uniontown15401	NCT04423211	Map
PA	UPMC Washington Hospital Radiation Oncology	Washington15301	NCT04423211	Map
PA	UPMC Susquehanna	Williamsport17701	NCT04423211	Map
PA	Main Line Health	Wynnewood19096	NCT06439524	Map
PA	UPMC Memorial	York17408	NCT04423211	Map
SC	Bluffton	Bluffton29910-4883	NCT05862272	Map
SC	Medical University of South Carolina	Charleston29425	NCT04423211	Map
SC	Greenville	Greenville29615-4833	NCT05862272	Map
SC	Summerville	Summerville29485-8345	NCT05862272	Map
SC	West Columbia	West Columbia29169	NCT05862272	Map
TN	Chattanooga	Chattanooga37404	NCT05862272	Map
TN	Jackson	Jackson38305	NCT05862272	Map
TN	Memphis	Memphis38119	NCT05862272	Map
TN	Memphis	Memphis38120	NCT05862272	Map
TX	Arlington	Arlington76012-4705	NCT05862272	Map
TX	Dallas	Dallas75230-2598	NCT05862272	Map
TX	Dallas	Dallas75230	NCT05862272	Map
TX	Parkland Memorial Hospital	Dallas75235	NCT04423211	Map
TX	UT Southwestern Simmons Cancer Center - RedBird	Dallas75237	NCT04423211	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT04423211	Map
TX	Fort Worth	Fort Worth76104-4141	NCT05862272	Map
TX	Tarrant County Hospital District/JPS Health Network	Fort Worth76104	NCT04423211	Map
TX	UT Southwestern/Simmons Cancer Center-Fort Worth	Fort Worth76104	NCT04423211	Map
TX	Galveston	Galveston77555	NCT05862272	Map
TX	Houston	Houston77021	NCT05862272	Map
TX	Houston	Houston77024	NCT05862272	Map
TX	Houston	Houston77030-4514	NCT05862272	Map
TX	Houston	Houston77054	NCT05862272	Map
TX	Michael E. DeBakey VA Medical Center, Houston, TX	Houston77030	NCT04787744	Map
TX	League City	League City77573	NCT05862272	Map
TX	Pearland	Pearland77584	NCT05862272	Map
TX	UT Southwestern Clinical Center at Richardson/Plano	Richardson75080	NCT04423211	Map
TX	San Antonio	San Antonio78230	NCT05862272	Map
TX	San Antonio	San Antonio78258	NCT05862272	Map
TX	Sugar Land	Sugar Land77479-1001	NCT05862272	Map
TX	Sugar Land	Sugar Land77479	NCT05862272	Map
TX	Webster	Webster77598-4081	NCT05862272	Map
UT	Pleasant Grove	Pleasant Grove84062-4097	NCT05862272	Map
UT	Huntsman Cancer Institute at University of Utah	Salt Lake City84112	NCT07216248	Map
UT	Salt Lake City	Salt Lake City84107	NCT05862272	Map
VA	Annandale	Annandale22003-7308	NCT05862272	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT04423211	Map
VA	Newport News	Newport News23606	NCT05862272	Map
VA	Hunter Holmes McGuire VA Medical Center, Richmond, VA	Richmond23249	NCT04787744	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT04423211	Map
VA	Virginia Beach	Virginia Beach23456-8125	NCT05862272	Map
WA	Providence Regional Cancer System-Aberdeen	Aberdeen98520	NCT04423211	Map
WA	PeaceHealth Saint Joseph Medical Center	Bellingham98225	NCT04423211	Map
WA	Providence Regional Cancer System-Centralia	Centralia98531	NCT04423211	Map
WA	Swedish Cancer Institute-Edmonds	Edmonds98026	NCT04423211	Map
WA	Providence Regional Cancer Partnership	Everett98201	NCT04423211	Map
WA	Swedish Cancer Institute-Issaquah	Issaquah98029	NCT04423211	Map
WA	Kadlec Clinic Hematology and Oncology	Kennewick99336	NCT04423211	Map
WA	Providence Regional Cancer System-Lacey	Lacey98503	NCT04423211	Map
WA	PeaceHealth Saint John Medical Center	Longview98632	NCT04423211	Map
WA	Skagit Regional Health Cancer Care Center	Mount Vernon98274	NCT04423211	Map
WA	FHCC at Northwest Hospital	Seattle98133	NCT04423211	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT04423211	Map
WA	Seattle	Seattle98105-4028	NCT05862272	Map
WA	Swedish Medical Center-Ballard Campus	Seattle98107	NCT04423211	Map
WA	Swedish Medical Center-Cherry Hill	Seattle98122-5711	NCT04423211	Map
WA	Swedish Medical Center-First Hill	Seattle98122	NCT04423211	Map
WA	University of Washington	Seattle98109	NCT06111781	Map
WA	University of Washington Medical Center - Montlake	Seattle98195	NCT04423211	Map
WA	PeaceHealth United General Medical Center	Sedro-Woolley98284	NCT04423211	Map
WA	Saint Michael Cancer Center	Silverdale98383	NCT04423211	Map
WA	Cancer Care Northwest - Spokane South	Spokane99202	NCT04423211	Map
WA	Cancer Care Northwest-North Spokane	Spokane99218	NCT04423211	Map
WA	PeaceHealth Southwest Medical Center	Vancouver98664	NCT04423211	Map
WA	Providence Saint Mary Regional Cancer Center	Walla Walla99362	NCT04423211	Map
WI	Langlade Hospital and Cancer Center	Antigo54409	NCT04423211	Map
WI	Marshfield Medical Center-EC Cancer Center	Eau Claire54701	NCT04423211	Map
WI	University of Wisconsin Carbone Cancer Center - Johnson Creek	Johnson Creek53038	NCT04423211	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT04423211	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT04423211	Map
WI	William S Middleton VA Medical Center	Madison53705	NCT04423211	Map
WI	William S. Middleton Memorial Veterans Hospital, Madison, WI	Madison53705-2254	NCT04787744	Map
WI	Marshfield Medical Center-Marshfield	Marshfield54449	NCT04423211	Map
WI	Clement J. Zablocki VA Medical Center, Milwaukee, WI	Milwaukee53295-1000	NCT04787744	Map
WI	Marshfield Medical Center - Minocqua	Minocqua54548	NCT04423211	Map
WI	Cancer Center of Western Wisconsin	New Richmond54017	NCT04423211	Map
WI	Aspirus Cancer Care - James Beck Cancer Center	Rhinelander54501	NCT04423211	Map
WI	Marshfield Medical Center-Rice Lake	Rice Lake54868	NCT04423211	Map
WI	Aspirus Cancer Care - Stevens Point	Stevens Point54481	NCT04423211	Map
WI	Marshfield Medical Center-River Region at Stevens Point	Stevens Point54482	NCT04423211	Map
WI	Aspirus Regional Cancer Center	Wausau54401	NCT04423211	Map
WI	Marshfield Medical Center - Weston	Weston54476	NCT04423211	Map
WI	Aspirus Cancer Care - Wisconsin Rapids	Wisconsin Rapids54494	NCT04423211	Map
WY	Memorial Hospital of Laramie County	Cheyenne82001	NCT04423211	Map

Browse Relugolix Trials by State

New York clinical trials Washington clinical trials Pennsylvania clinical trials Missouri clinical trials Alaska clinical trials Georgia clinical trials Illinois clinical trials Texas clinical trials Oregon clinical trials California clinical trials

relugolixprostate cancerprostate adenocarcinomastage iii prostate cancer ajcc v8uterine fibroidsheavy menstrual bleedingclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

Recent Relugolix updates

What Is Relugolix?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Relugolix Development Timeline

Conditions Under Study

All Relugolix Clinical Trials (53)

Sponsors

Where to Participate: All Relugolix Trial Sites in the U.S. (439 sites across 41 states)

Browse Relugolix Trials by State